Nanobiotix (NASDAQ:NBTX - Get Free Report) is expected to be releasing its earnings data before the market opens on Wednesday, March 26th. Analysts expect Nanobiotix to post earnings of ($0.58) per share and revenue of $3.55 million for the quarter.
Nanobiotix Stock Down 2.9 %
Shares of NASDAQ NBTX traded down $0.10 during trading on Wednesday, hitting $3.48. 19,626 shares of the company were exchanged, compared to its average volume of 22,037. Nanobiotix has a 12-month low of $2.76 and a 12-month high of $7.51. The company has a fifty day moving average price of $3.54 and a 200-day moving average price of $3.87.
Wall Street Analysts Forecast Growth
Separately, UBS Group raised Nanobiotix to a "hold" rating in a research report on Monday, February 17th.
Read Our Latest Report on Nanobiotix
About Nanobiotix
(
Get Free Report)
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
See Also
Before you consider Nanobiotix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nanobiotix wasn't on the list.
While Nanobiotix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
